170 related articles for article (PubMed ID: 38702621)
1. Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.
Wei G; Zhao Y; Feng S; Yuan J; Xu G; Lv T; Yang J; Kong L; Yang J
BMC Cancer; 2024 May; 24(1):558. PubMed ID: 38702621
[TBL] [Abstract][Full Text] [Related]
2. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Qiu B; Li K; Dong X; Liu FQ
Cardiovasc Intervent Radiol; 2017 Sep; 40(9):1372-1382. PubMed ID: 28488102
[TBL] [Abstract][Full Text] [Related]
3. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
[TBL] [Abstract][Full Text] [Related]
4. Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis.
Zhao JB; Feng C; Zhu QH; He XF; Li YH; Chen Y
World J Gastroenterol; 2014 Feb; 20(6):1602-7. PubMed ID: 24587637
[TBL] [Abstract][Full Text] [Related]
5. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion.
Kim JM; Kwon CH; Joh JW; Ko JS; Park JB; Lee JH; Kim SJ; Paik SW; Park CK
World J Surg Oncol; 2013 Apr; 11():92. PubMed ID: 23618082
[TBL] [Abstract][Full Text] [Related]
7. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Yamamoto Y; Ikoma H; Morimura R; Shoda K; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Kubota T; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Sakakura C; Ochiai T; Otsuji E
World J Gastroenterol; 2015 Jan; 21(1):246-53. PubMed ID: 25574098
[TBL] [Abstract][Full Text] [Related]
8. Alpha-fetoprotein and
Yang Z; Luo FZ; Wang S; Lerut J; Zhuang L; Li QY; Xu X; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):229-234. PubMed ID: 32303439
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
10. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension.
Zhong JH; Li H; Xiao N; Ye XP; Ke Y; Wang YY; Ma L; Chen J; You XM; Zhang ZY; Lu SD; Li LQ
PLoS One; 2014; 9(9):e108755. PubMed ID: 25268959
[TBL] [Abstract][Full Text] [Related]
11. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
Wei J; Li H; Li C
J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
[TBL] [Abstract][Full Text] [Related]
12. Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation.
Faitot F; Allard MA; Pittau G; Ciacio O; Adam R; Castaing D; Cunha AS; Pelletier G; Cherqui D; Samuel D; Vibert E
Hepatology; 2015 Jul; 62(1):179-87. PubMed ID: 25914217
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma.
Bettinger D; Knüppel E; Euringer W; Spangenberg HC; Rössle M; Thimme R; Schultheiß M
Aliment Pharmacol Ther; 2015 Jan; 41(1):126-36. PubMed ID: 25329493
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival.
Chagas AL; Felga GEG; Diniz MA; Silva RF; Mattos AA; Silva RCMA; Boin IFSF; Garcia JHP; Lima AS; Coelho JCU; Bittencourt PL; Alves VAF; D'Albuquerque LAC; Carrilho FJ;
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1148-1156. PubMed ID: 31247632
[TBL] [Abstract][Full Text] [Related]
15. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation.
Lee KW; Suh SW; Choi Y; Jeong J; Yi NJ; Kim H; Yoon KC; Hong SK; Kim HS; Lee KB; Suh KS
Liver Transpl; 2017 Jan; 23(1):19-27. PubMed ID: 27540701
[TBL] [Abstract][Full Text] [Related]
16. Outcome of liver transplantation for hepatocellular carcinoma -- a single center experience.
Iacob R; Iacob S; Gheorghe L; Gheorghe C; Hrehoreţ D; Brașoveanu V; Croitoru A; Herlea V; Popescu I
Chirurgia (Bucur); 2013; 108(4):446-50. PubMed ID: 23958083
[TBL] [Abstract][Full Text] [Related]
17. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
[TBL] [Abstract][Full Text] [Related]
18. Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series.
Sapisochin G; Bilbao I; Balsells J; Dopazo C; Caralt M; Lázaro JL; Castells L; Allende H; Charco R
World J Surg; 2010 Sep; 34(9):2146-54. PubMed ID: 20411387
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II.
Lv JY; Zhang NN; Du YW; Wu Y; Song TQ; Zhang YM; Qu Y; Liu YX; Gu J; Wang ZY; Qiu YB; Yang B; Tian DZ; Guo QJ; Zhang L; Sun JS; Xie Y; Wang ZL; Sun X; Jiang WT; Lu W
Yonsei Med J; 2021 Jan; 62(1):29-40. PubMed ID: 33381932
[TBL] [Abstract][Full Text] [Related]
20. Liver transplantation and hepatocellular carcinoma: is TIPS deleterious? A multicentric retrospective study of the ARCHET research group with propensity score matching.
Laurent C; Rayar M; Maulat C; Muscari F; Marichez A; Gregoire E; Chopinet S; Mabrut JY; Boudjema K; Lesurtel M; Adam JP; Mohkam K; Chiche L
Langenbecks Arch Surg; 2023 Apr; 408(1):149. PubMed ID: 37052722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
